A Study To Evaluate The Effectiveness And Safety Of Ravulizumab In Adult Participants With Neuromyelitis Optica Spectrum Disorder

Overview

About this study

The primary purpose of this study is to evaluate the effectiveness and safety of Ravulizumab for the treatment of adult participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Anti-aquaporin-4 antibody-positive and a diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria.
  • At least 1 attack or relapse in the last 12 months prior to the Screening Period.
  • Expanded Disability Status Scale score ≤ 7.
  • Participants who enter the study receiving supportive immunosuppressive therapy must be on a stable dosing regimen of adequate duration prior to Screening.
  • Body weight ≥40 kilograms.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

  • History of neisseria meningitidis infection.
  • Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody titer).
  • Previously or currently treated with a complement inhibitor.
  • Use of rituximab or mitoxantrone within 3 months prior to Screening.
  • Use of IV immunoglobulin within 3 weeks prior to Screening.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sean Pittock, M.D.

Closed for enrollment

Contact information:

Center for Multiple Sclerosis and Autoimmune Neurology

DLCMSANResCoor@mayo.edu

More information

Publications

Publications are currently not available